MDT-AP-2910
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 1
- new_clusters
- S2
- umap1_2d
- -0.856111289
- umap2_2d
- -8.909443332
- umap1_3d
- -3.083766464
- umap2_3d
- -1.852911083
- umap3_3d
- 5.669157537
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- PANCREAS_BETA_CELLS+0.470
- INFLAMMATORY_RESPONSE+0.460
- ALLOGRAFT_REJECTION+0.450
- UV_RESPONSE_DN+0.430
- COMPLEMENT+0.420
- ANDROGEN_RESPONSE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
Top 10 suppressed
- DNA_REPAIR-0.340
- MYC_TARGETS_V2-0.280
- MITOTIC_SPINDLE-0.170
- WNT_BETA_CATENIN_SIGNALING-0.170
- E2F_TARGETS-0.120
- HEME_METABOLISM-0.120
- ADIPOGENESIS+0.000
- OXIDATIVE_PHOSPHORYLATION+0.010
- BILE_ACID_METABOLISM+0.020
- FATTY_ACID_METABOLISM+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG639 | — | — | 0.903 |
| 2 | SRR1797276 | — | cohortMD2 | 0.894 |
| 3 | MDT-AP-2902 | Med | Medulloblastoma | 0.894 |
| 4 | MDT-AP-0815 | Med | Medulloblastoma | 0.892 |
| 5 | 59627_S122 | — | cohortA4 | 0.890 |
| 6 | SRR10900576 | — | — | 0.886 |
| 7 | DRR168605 | — | — | 0.880 |
| 8 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.878 |
| 9 | MDT-AP-0173 | Med | Medulloblastoma | 0.876 |
| 10 | MDT-AP-2149 | Med | Medulloblastoma | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.470 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| APOPTOSIS | 0.340 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |